Skin microbiome changes with lebrikizumab for eczema
Part of Genetic & congenital, Immune system & allergy, Skin clinical trials.
This study looks at how lebrikizumab, a biologic medicine for atopic dermatitis (eczema), affects the skin's microbiome (the natural community of microorganisms on your skin). It aims to see if changes in the skin's microbiome are linked to treatment response.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older
- You must have a diagnosis of atopic dermatitis (eczema)
- You must be starting treatment with lebrikizumab
- You must not have been treated with lebrikizumab before
- You must not be currently using other biologic medications or JAK inhibitors
- You must not have an allergy to lebrikizumab or its ingredients
- You must not be pregnant or breastfeeding
- You must not have an active helminth (worm) infection
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how lebrikizumab (Ebglyss) affects daily life and skin symptoms in adults with moderate-to-severe eczema. You may join if your doctor has prescribed this medication as part of your regular care.
This study looks at molecular (body-level) signatures in people with chronic inflammatory skin conditions. You may help researchers understand what drives inflammation, while receiving standard (already approved) systemic treatment through routine care.
This Phase 3 trial studies whether lebrikizumab is safe and continues to work over the long term for children and teens with moderate-to-severe atopic dermatitis (eczema). It’s meant for people who already finished a related earlier study and can safely continue.
This study tests how well lebrikizumab (Ebglyss), an approved treatment for moderate-to-severe atopic dermatitis (eczema), works in everyday clinical practice. It aims to see how the drug affects your symptoms and quality of life over time, helping guide better treatment decisions.
This study tests a new injected medicine, lebrikizumab, for people whose eczema mainly affects the face and neck. It aims to see if it can improve these hard-to-treat areas.
This study looks at the types of germs on the skin (skin microbiome) in healthy people and people with skin conditions, including atopic dermatitis (eczema). Researchers collect skin samples to understand how skin germs differ and how that may relate to skin health.
Hear when a new Atopic Dermatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.